Table 3.
Between-group analysis of different outcome measures in weeks 0, 6 and 12.
| Variables | Rivastigmine | Placebo | t | p | CI |
|---|---|---|---|---|---|
| PANSS-positive symptoms week 0 | 16.2 ± 4.4 | 15.4 ± 4 | 0.57 | 0.57 | −2.05, 3.65 |
| PANSS-positive symptoms week 6 | 15.2 ± 4.9 | 15.3 ± 3.8 | −0.06 | 0.94 | −3.07, 2.87 |
| PANSS-positive symptoms week 12 | 14.2 ± 4.4 | 13.8 ± 4.1 | 0.28 | 0.77 | −2.48, 3.28 |
| PANSS-negative symptoms week 0 | 19.6 ± 9.2 | 21.1 ± 9.1 | −0.49 | 0.62 | −7.70, 4.70 |
| PANSS-negative symptoms week 6 | 18.1 ± 9.1 | 20.4 ± 9.1 | −0.75 | 0.45 | −8.46, 3.86 |
| PANSS-negative symptoms week 12 | 17.2 ± 9.6 | 19 ± 9 | −0.58 | −0.58 | −8.10, 4.50 |
| PANSS-general psychopathology week 0 | 36.1 ± 7.6 | 38.5 ± 8.2 | −0.91 | 0.36 | −7.76, 2.96 |
| PANSS-general psychopathology week 6 | 35.3 ± 7.1 | 37.7 ± 7.9 | −0.95 | −0.95 | −7.49, 2.69 |
| PANSS-general psychopathology week 12 | 34.6 ± 6.9 | 37.5 ± 7.8 | −1.18 | 0.24 | −7.89, 2.09 |
| MMSE week 0 | 24.1 ± 2.9 | 23 ± 3.2 | 1.08 | 0.28 | −0.97, 3.17 |
| MMSE week 6 | 26.1 ± 2.9 | 23.3 ± 3.2 | 2.75 | 0.009 | 0.73, 4.87 |
| MMSE week 12 | 27.1 ± 2.1 | 23.1 ± 3.2 | 4.43 | 0.0001 | 2.17, 5.83 |
| CGI-I week 0 | 3.03 ± 0.14 | 3.06 ± 0.26 | −0.43 | 0.66 | −0.17, 0.11 |
| CGI-I week 6 | 3.00 ± 0.29 | 3.05 ± 0.13 | −0.66 | 0.50 | −0.20, 0.10 |
| CGI-I week 12 | 2.66 ± 0.78 | 3.01 ± 0.38 | −1.71 | 0.09 | −0.77, 0.07 |
| ESRS week 0 | 8.7 ± 2.6 | 9 ± 2.6 | −0.34 | 0.73 | −2.06, 1.46 |
| ESRS week 6 | 9.1 ± 3.4 | 10.1 ± 2.5 | −1.00 | 0.32 | −3.02, 1.02 |
| ESRS week12 | 10 ± 3.4 | 10 ± 2.5 | 0.00 | 1.00 | −2.02, 2.02 |
CGI-I, Clinical Global Impressions-Improvement; ESRS, Extrapyramidal Symptom Rating Scale; MMSE, Mini Mental State Examination; PANSS, Positive and Negative Symptom Scale.